IL-1 β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C

• Published in: Digestive diseases and sciences 1996-02, Vol.41 (2), p.315-321
• Main Authors: KISHIHARA, Y, HAYASHI, J, YOSHIMURA, E, YAMAJI, K, NAKASHIMA, K, KASHIWAGI, S
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Chronic Disease; Female; Hepacivirus - genetics; Hepatitis C - blood; Hepatitis C - therapy; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - therapeutic use; Interleukin-1 - blood; Interleukin-1 - metabolism; Leukocytes, Mononuclear - metabolism; Male; Medical sciences; Middle Aged; Molecular Sequence Data; RNA, Viral - blood; Tumor Necrosis Factor-alpha - metabolism; Viral diseases; Viral hepatitis
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/BF02093821

We investigated the spontaneous and phytohemagglutinin-stimulated production of interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) by peripheral blood mononuclear cells in patients with chronic hepatitis C during treatment with interferon-alpha (IFN-alpha). Spontaneous productions of these were significantly higher in patients with chronic hepatitis C than in healthy subjects. For patients prescribed interferon, stimulated production of TNF-alpha was significantly higher in complete responders than in partial responders, but the differences were small between the other cytokine levels and outcome of IFN treatment. Spontaneous production of these cytokines was higher in patients with genotype III with complete response than in genotype III patients with a partial response, but this was not the case in patients with genotype II. There was a negative correlation between these cytokines and histological activity index. Spontaneous production of cytokines was decreased only in complete responders after the administration of interferon. These data suggest that the elevated production of cytokines in patients with chronic hepatitis C may be due to host response to the virus, and monitoring cytokines along with alanine aminotransferase and hepatitis C virus RNA during treatment may provide more precise information of the effectiveness of therapy.